300 related articles for article (PubMed ID: 12638471)
21. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation.
O'Meara LC; Alten JA; Goldberg KG; Timpa JG; Phillips J; Laney D; Borasino S
ASAIO J; 2015; 61(3):339-44. PubMed ID: 25710768
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant activity and pleiotropic effects of heparin.
Bal Dit Sollier C; Dillinger JG; Drouet L
J Med Vasc; 2020 May; 45(3):147-157. PubMed ID: 32402428
[TBL] [Abstract][Full Text] [Related]
23. Are low-molecular-weight heparins safe and effective in children? A systematic review.
Klaassen ILM; Sol JJ; Suijker MH; Fijnvandraat K; van de Wetering MD; Heleen van Ommen C
Blood Rev; 2019 Jan; 33():33-42. PubMed ID: 30041977
[TBL] [Abstract][Full Text] [Related]
24. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
25. Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women.
Xiao S; Luo Y; Guo L; Zhang J; Mu L; Ye Z
J Investig Med; 2022 Mar; 70(3):773-779. PubMed ID: 34921124
[TBL] [Abstract][Full Text] [Related]
26. Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review.
Kjaergaard AB; Fuglsang J; Hvas AM
Semin Thromb Hemost; 2021 Oct; 47(7):824-842. PubMed ID: 34130342
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
[TBL] [Abstract][Full Text] [Related]
28. Unfractionated Heparins, Low-Molecular-Weight Heparins, and Indirect Factor Xa Inhibitors in Plastic and Reconstructive Surgery: An Evidence-Based Review.
Othman S; Bertolaccini CM; Pannucci CJ
Plast Reconstr Surg; 2024 Jun; 153(6):1224e-1231e. PubMed ID: 37189249
[TBL] [Abstract][Full Text] [Related]
29. Effects of low molecular weight heparin in the treatment of venous thromboembolism in patients with gastrointestinal cancer.
Hu YR; Liu YY; Liu LP; Zhang H
J Biol Regul Homeost Agents; 2018; 32(3):673-679. PubMed ID: 29921398
[TBL] [Abstract][Full Text] [Related]
30. Factors Influencing ACT After Intravenous Bolus Administration of 100 IU/kg of Unfractionated Heparin During Cardiac Catheterization in Children.
Muster I; Haas T; Quandt D; Kretschmar O; Knirsch W
Clin Appl Thromb Hemost; 2017 Oct; 23(7):740-747. PubMed ID: 27514640
[TBL] [Abstract][Full Text] [Related]
31. Patients' Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips.
Harenberg J; Hetjens S; Weiss C
Clin Appl Thromb Hemost; 2022; 28():10760296221083667. PubMed ID: 35275493
[TBL] [Abstract][Full Text] [Related]
32. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
[TBL] [Abstract][Full Text] [Related]
33. Heparin monitoring: clinical outcome and practical approach.
Despas N; Larock AS; Jacqmin H; Douxfils J; Chatelain B; Chatelain M; Mullier F
Ann Biol Clin (Paris); 2016 Dec; 74(6):637-652. PubMed ID: 27848915
[TBL] [Abstract][Full Text] [Related]
34. A less-intensive anticoagulation protocol of therapeutic unfractionated heparin administration for pregnant patients.
Neki R; Mitsuguro M; Okamoto A; Ida K; Miyoshi T; Kamiya C; Iwanaga N; Miyata T; Yoshimatsu J
Int J Hematol; 2019 Nov; 110(5):550-558. PubMed ID: 31347027
[TBL] [Abstract][Full Text] [Related]
35. Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery.
Iliuta L; Andronesi A; Camburu G; Rac-Albu M
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013586
[TBL] [Abstract][Full Text] [Related]
36. Effect of antithrombotic drugs on bone health.
Dadwal G; Schulte-Huxel T; Kolb G
Z Gerontol Geriatr; 2020 Aug; 53(5):457-462. PubMed ID: 31414167
[TBL] [Abstract][Full Text] [Related]
37. Clinical study on low-molecular weight heparin infusion as anticoagulation for nocturnal home haemodialysis.
Wong SS; Lau WY; Ng ML; Chan SY; Chan SF; Chan PK; Wan CK; Cheng YL
Nephrology (Carlton); 2018 Apr; 23(4):317-322. PubMed ID: 28052451
[TBL] [Abstract][Full Text] [Related]
38. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.
Krieter DH; Fink S; Dorsch O; Harenberg J; Melzer N; Wanner C; Lemke HD
Artif Organs; 2015 Nov; 39(11):951-9. PubMed ID: 25900127
[TBL] [Abstract][Full Text] [Related]
40. Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support.
Moynihan K; Johnson K; Straney L; Stocker C; Anderson B; Venugopal P; Roy J
Perfusion; 2017 Nov; 32(8):675-685. PubMed ID: 28693359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
